中 | EN
  • Home
  • About Us
    1. Introduction
    2. Subsidiaries
    3. Vision & Culture
    4. History
  • Products
  • R&D
    1. R&D Team
    2. Technical Platform
    3. Upcoming Products
  • Investors
    1. Corporate Data
    2. Announcements
    3. Financial Reports
    4. Offering Documents
    5. Corporate Governance
    6. Investor Query
  • News
    1. Dynamics
    2. Media Reports
    3. Media Inquiry
  • Career
    1. Talents
    2. Jobs
  • Contact

NEWS

Home > News > Dynamics >

Development of Bivalent mRNA Vaccines against SARS-CoV-2 Varinats

2022-10-27 Source:



Previous:EV71-CA16 BIVALENT HFMD VACCINE CANDIDATE OBTAINED THE  CLINICAL TRIAL APPROVAL ISSUED BY THE NATIONAL  MEDICAL PRODUCTS ADMINISTRATION Next:FREEZE-DRIED HUMAN RABIES VACCINE CANDIDATE  (SERUM-FREE VERO CELL) OBTAINED THE CLINICAL TRIAL APPROVAL ISSUED BY THE  NATIONAL MEDICAL PRODUCTS ADMINISTRATION
  • About Us

    1. Introduction
    2. Vision & Culture
    3. History
    4. Subsidiaries
  • Products

    1. Recombinant Hepatitis B Vaccine
    2. Freeze-dried Human Rabies Vaccine
    3. Inactivated Hepatitis A Vaccine
    4. Live Attenuated Parotitis Vaccine
    5. Inactivated HFRS Vaccine
    6. ACYW135 Meningococcus Polysaccharide Vaccine
  • R&D

    1. R&D Team
    2. Technical Platform
    3. Upcoming Products
  • Investors

    1. Corporate Data
    2. Announcements
    3. Financial Reports
    4. Offering Documents
    5. Corporate Governance
    6. Investor Query
  • Career

    1. Talents
    2. Jobs
    3. Corporate WeChat

  • Links

    1. National Health Commission of the People’s Republic of China
    2. National Medical Products Administration
    3. Chinese Center for Disease Control and Prevention
    4. National Institutes for Food and Drug Control
    5. Chinese Journal of Vaccines and Immunization
© 2022 艾美疫苗股份有限公司 All rights reserved. 京ICP备20027818号-1 京公网安备11010502045274号